FY2027 IPPS took effect October 1 with a 2.3% operating rate update for compliant hospitals. The headline is not a revenue forecast. Here is what CFOs are actually modeling, and how to separate the final inpatient rule from the proposed outpatient policies still pending.
As of October 1, 2026, the FY2027 Medicare Hospital Inpatient Prospective Payment System (IPPS) final rule is effective. The headline figure is a 2.3% net operating payment rate update for hospitals that meet two qualifying conditions: successful participation in the Hospital Inpatient Quality Reporting (IQR) program and meaningful use of a certified electronic health record (EHR) system. That 2.3% reflects a 3.2% market basket increase reduced by a 0.9 percentage-point productivity adjustment, as established in the final rule CMS published earlier this year.
Hospitals that fail to submit the required IQR quality data but remain meaningful EHR users receive a 1.5% update, one percentage point below the full update. The financial downside is greater where a hospital also fails the meaningful-EHR-user requirement: the FY2027 operating update is -0.1% for hospitals that satisfy IQR but not meaningful-use requirements, and -0.9% for hospitals that satisfy neither.
On $400 million of modeled IPPS operating payments, the 0.8-point difference between a 2.3% and 1.5% update is approximately $3.2 million before hospital-specific payment adjustments. Finance, quality, informatics, and compliance teams should confirm the hospital's IQR submission status and meaningful-EHR-user status, including any applicable exceptions or hardship determinations, before finalizing revenue assumptions.
The 2.3% update is applied to the standardized operating base rate. It is not a statement about what any individual hospital will collect, and it should not flow directly into a revenue forecast without adjustment. It also does not describe the separate capital payment update, or hospital-specific teaching, IME, outlier, new-technology, DSH, and uncompensated-care payment effects that can materially change total IPPS reimbursement. CMS finalized a 3.4% update to the federal capital rate, separate from the 2.3% operating-rate update (3.1% capital input price index increase plus a 0.3-point forecast-error correction).
The 2.3% figure is a national policy lever. What arrives on a hospital's revenue line is the product of hospital-specific factors that CMS adjusts individually. Treating the standardized rate update as a revenue growth number is one of the more persistent modeling errors in hospital finance.
Wage index is often one of the most consequential local payment adjusters. The IPPS standardized amount is divided into labor-related and non-labor shares. CMS adjusts the labor-related share using the applicable area wage index, while the non-labor-related share is not wage-index adjusted. Hospitals whose applicable wage index declines relative to FY2026 can see the national operating-rate update partially offset in their realized payment calculation. Hospitals near Core-Based Statistical Area (CBSA) boundary reclassifications can see step-change effects in either direction.
Case mix index (CMI) moves independently of rate updates. A hospital whose documented CMI declined because coding intensity or clinical severity shifted will receive less revenue per discharge, regardless of what the base rate did. Conversely, a hospital that invested in clinical documentation improvement programs and captured previously undercoded complexity may realize revenue growth that significantly exceeds the base rate update. The base rate establishes one input to payment. Case mix, MS-DRG assignment, coding and documentation quality, volume, and hospital-specific payment adjustments determine the realized payment per discharge and total inpatient revenue.
Disproportionate share hospital (DSH) payments and uncompensated care distributions can move significantly year-over-year independent of the base rate. For hospitals eligible for Medicare DSH payments, FY2027 payment includes a traditional DSH component and a separate uncompensated-care payment. CMS calculates the uncompensated-care distribution using statutory factors, including the national pool and each eligible hospital's relative uncompensated-care share; for FY2027, CMS finalized use of audited FY2021 through FY2023 cost-report data to determine that share. CMS estimates FY2027 uncompensated-care and supplementary payments at approximately $7.94 billion, using audited FY2021 through FY2023 cost-report data to determine hospital-specific relative uncompensated-care shares. For safety-net hospitals, these two components often dwarf the impact of a one-percentage-point swing in the operating rate.
Medicare volume and payer mix are perhaps the variables most under-modeled in annual budget cycles. Volume shifts to outpatient settings, growth in Medicare Advantage penetration reducing traditional fee-for-service IPPS cases, and payer mix changes driven by Medicaid expansion or commercial contracting all sit outside the rate-update calculus entirely.
The CFO's job at this point in the year is to run the FY2027 IPPS model with final rule parameters, hospital-specific wage index, updated CMI projections, and current uncompensated care pool estimates, then to stress-test the result. The 2.3% is the starting point, not the answer.
A separate set of proposed policies governs Medicare outpatient payment, and they carry meaningful financial exposure for hospitals with significant outpatient volume or 340B Drug Pricing Program participation. These are not effective now. They are proposals under the Calendar Year 2027 Outpatient Prospective Payment System (OPPS) proposed rule, which CMS released for public comment earlier this year. If finalized, they would generally take effect January 1, 2027. Nothing in CY2027 OPPS is final as of this writing.
The most consequential proposal is a dramatic restructuring of 340B drug payment rates. For affected separately payable drugs acquired through the 340B Program, CMS proposes payment at ASP minus 33.4%, replacing the current general OPPS payment approach of ASP plus 6%. CMS bases the proposal on its hospital acquisition-cost survey. [verify: confirm ASP-33.4% figure and $4.55B estimate against CMS CY2027 OPPS proposed rule fact sheet] The proposal's practical effect depends on hospital type, drug status, pass-through treatment, product mix, and applicable OPPS payment exceptions. If the survey methodology holds and the rule is finalized as proposed, CMS estimates a reduction of approximately $4.55 billion in Medicare drug payments in the first year. CMS proposes to redistribute the estimated savings through a budget-neutral increase in the non-drug OPPS conversion factor. That means the policy redistributes payment rather than simply reducing aggregate OPPS spending: hospitals with relatively low exposure to 340B separately payable drugs may benefit, while hospitals with high 340B drug volume may lose materially.
The second outpatient proposal addresses the 340B remedy recovery. After CMS made lump-sum remedy payments to hospitals affected by the earlier 340B payment policy, it implemented an offset to recover the associated budget-neutrality adjustment through non-drug OPPS payments. The existing offset is 0.5%; CMS proposes increasing it to 3% for CY2027. [verify: confirm 0.5% to 3% acceleration and hospital eligibility criteria against CMS CY2027 OPPS proposed rule] CMS has proposed to exempt hospitals that enrolled in Medicare on or after January 1, 2018, on the basis that those facilities were not affected by the original payment reductions being remedied. Hospitals that were enrolled in Medicare before January 1, 2018 and are not otherwise excluded should model the proposed 3% non-drug OPPS offset as a downside scenario.
This is a non-drug OPPS conversion-factor reduction tied specifically to the 340B litigation remedy. It is not a disproportionate share hospital payment adjustment. The DSH and 340B remedy mechanisms are operationally distinct, and conflating them produces incorrect financial models.
The third proposal extends site-neutral payment into a new category of services. CMS proposes to extend site-neutral payment to specified imaging services without contrast furnished in excepted off-campus provider-based departments. CMS estimates the provision would reduce Part B expenditures by approximately $260 million in CY2027. [verify: confirm non-contrast imaging site-neutral expansion against CMS CY2027 OPPS proposed rule] Hospitals with large excepted off-campus imaging volumes should identify how much of that volume falls into non-contrast categories and quantify the per-procedure payment differential under the proposed methodology.
| Policy | Status on October 5, 2026 | Planning implication |
|---|---|---|
| FY2027 IPPS operating-rate update | Final and effective October 1 | Use final 2.3%/1.5%/-0.1%/-0.9% operating-update categories in the model |
| FY2027 capital-rate update | Final and effective October 1 | Use final 3.4% federal capital-rate update |
| FY2027 DSH/UCC methodology | Final | Model hospital-specific share using final CMS parameters |
| 340B ASP minus 33.4% proposal | Proposed CY2027 OPPS policy | Model separately payable 340B drug exposure |
| 340B remedy offset of 3% | Proposed CY2027 OPPS policy | Model downside on non-drug OPPS payments |
| Site-neutral non-contrast imaging | Proposed CY2027 OPPS policy | Model excepted off-campus imaging exposure |
The timing split here matters operationally. FY2027 IPPS is final and already running. CY2027 OPPS is proposed and pending finalization. These require two separate modeling tracks, and collapsing them into a single revenue adjustment is a mistake.
For IPPS, the work is straightforward and should be in process now. Pull final FY2027 wage index tables, confirm your CBSA classification and any reclassification applications, update CMI projections with documentation improvement actuals, and run hospital-specific uncompensated-care projections using CMS's final FY2027 pool parameters and the hospital's expected relative share. Build the FY2027 IPPS model on final CMS rate and policy parameters, while continuing to forecast hospital-specific volume, case mix, payer mix, outlier exposure, and uncompensated-care share.
For OPPS, build a sensitivity model with at minimum three scenarios: A baseline scenario in which the proposed 340B, remedy-recovery, and imaging changes do not take effect, the proposed rule finalized as written, and a partial or modified final rule that adjusts the 340B rate but not the remedy acceleration (or vice versa). Inputs to isolate: total 340B drug volume billed to Medicare outpatient, separately payable drug mix versus bundled drug exposure, non-drug OPPS conversion factor base, revenue from excepted off-campus PBDs broken out by imaging modality, and your hospital's Medicare enrollment date relative to January 1, 2018 for remedy-recovery eligibility analysis.
The initial sensitivity model need not predict the final rule perfectly, but it should quantify a credible exposure range before the final OPPS rule is released. It needs to establish the range of exposure so that leadership is not reading a finalized OPPS rule in November and building a budget revision from scratch in December. At the largest high-volume 340B systems, the exposure could be substantial, potentially reaching eight or nine figures depending on separately payable drug volume, acquisition costs, hospital exemptions, and the final rule's design. Organizations should calculate facility-level exposure rather than extrapolate from CMS's national estimate. The remedy acceleration compounds that. Waiting for finalization to begin modeling is not a risk management posture. It is a gap.
The FY2027 IPPS rate update is 2.3% for compliant hospitals. That sentence is accurate and complete. What it does not tell you is whether your hospital's Medicare inpatient revenue line is growing, flat, or declining in FY2027, and it says nothing about what happens to your outpatient book of business if CMS finalizes CY2027 OPPS as proposed. Both of those are modeling problems, not headline problems.
Discover how Addie helps health systems, post-acute providers, and payers improve throughput, reduce avoidable days, and deliver better transitions of care.
Get Started
